-
-
-
-
-
-
-
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
15,818 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

